LENZ · RA Capital Management filed an SC 13D/A disclosing that it sold its…

RA Capital Management filed an SC 13D/A disclosing that it sold its entire stake in LENZ Therapeutics on October 29-30 and November 2, 2026, reducing its beneficial ownership to 70,533 shares (all warrants) representing 0.2% of shares outstanding. The filing states RA Capital ceased to be a beneficial owner of more than 5% on October 29, 2026, marking a complete exit from the stock.

• RA Capital sold 2,159,516 shares on 10/29/2026 at avg $3.36, 528,405 shares on 10/30/2026 at avg $3.27, and 631,418 shares on 11/02/2026 at avg $2.98 through the Fund
• Nexus Fund II sold 451,998 shares on 10/29, 110,599 on 10/30, and 132,158 on 11/02 at same average prices
• Account sold 107,170 shares on 10/29, 26,222 on 10/30, and 31,337 on 11/02 at same average prices
• Total shares sold: approximately 4,178,823 shares across all entities